Page last updated: 2024-08-23

pirfenidone and Dyspnea

pirfenidone has been researched along with Dyspnea in 16 studies

Research

Studies (16)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's14 (87.50)24.3611
2020's2 (12.50)2.80

Authors

AuthorsStudies
Aguilar-Medina, S; Alva-Lopez, LF; Cazzola, M; Domínguez-Arellano, S; Escobar-Alvarado, JC; Falfán-Valencia, R; Matera, MG; Montiel-Lopez, F; Olaya-López, E; Pérez-Rubio, G; Poo, JL; Ramírez-Venegas, A; Sansores, RH; Zavaleta-Martínez, EO1
Antoniou, K; Kamekis, A; Kokosi, M; Swigris, JJ; Symvoulakis, EK1
Lederer, DJ; Martinez, FJ1
Kishaba, T1
Black, KE; Feneis, JF; Mark, EJ; Montesi, SB1
Dobashi, K; Hachisu, Y; Hisada, T; Izuhara, K; Kaira, K; Koga, Y; Ohta, S; Ono, J; Tsurumaki, H; Yatomi, M1
Albera, C; Behr, J; Chou, W; Costabel, U; Kirchgaessler, KU; Limb, SL; Morgenthien, E; Nathan, SD; Noble, PW; Stauffer, JL; Wuyts, WA1
Albera, C; Gilberg, F; Glassberg, MK; Kirchgaessler, KU; Petzinger, U; Wijsenbeek, MS1
Egan, J1
Fukuda, Y; Goto, H; Hanibuchi, M; Morizumi, S; Nishioka, Y; Sato, S; Takahashi, M; Toyoda, Y1
Bradford, WZ; Collard, HR; du Bois, RM; Ley, B; Vittinghoff, E; Weycker, D1
Hanada, S; Kishi, K; Kurosaki, A; Miyamoto, A; Mochizuki, S; Morokawa, N; Murase, K; Ogawa, K; Takahashi, Y; Takaya, H; Takeyasu, M; Uruga, H1
Albera, C; Costabel, U; Fagan, EA; Glassberg, MK; Gorina, E; Lancaster, L; Lederer, DJ; Nathan, SD; Spirig, D; Swigris, JJ1
Hosein, K; Le, J; Mura, M1
Celik, G; Ciledağ, A; Cirit Koçer, B; Kaya, A; Köktürk, N; Numanoğlu, N1
Bajwah, S; Higginson, IJ; Koffman, J; Patel, AS; Peacock, JL; Riley, J; Ross, JR; Wells, AU1

Reviews

4 review(s) available for pirfenidone and Dyspnea

ArticleYear
Burden of idiopathic pulmonary fibrosis on patients' emotional well being and quality of life: a literature review.
    Current opinion in pulmonary medicine, 2020, Volume: 26, Issue:5

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cough; Dyspnea; Fatigue; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Mental Health; Protein Kinase Inhibitors; Pyridones; Quality of Life

2020
Idiopathic Pulmonary Fibrosis.
    The New England journal of medicine, 2018, May-10, Volume: 378, Issue:19

    Topics: Diagnosis, Differential; Dyspnea; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Oxygen Inhalation Therapy; Prognosis; Pyridones; Risk Factors; Tomography, X-Ray Computed; Transforming Growth Factor beta

2018
Evaluation and management of Idiopathic Pulmonary Fibrosis.
    Respiratory investigation, 2019, Volume: 57, Issue:4

    Topics: Biomarkers; Chronic Disease; Cough; Diagnosis, Differential; Disease Progression; Dyspnea; Humans; Idiopathic Pulmonary Fibrosis; Indoles; L-Lactate Dehydrogenase; Mucin-1; Pyridones; Respiratory Function Tests; Tomography, X-Ray Computed; Vital Capacity

2019
Interventions to improve symptoms and quality of life of patients with fibrotic interstitial lung disease: a systematic review of the literature.
    Thorax, 2013, Volume: 68, Issue:9

    Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Cough; Dyspnea; Exercise Test; Fibrosis; Glucocorticoids; Heroin; Humans; Immunologic Factors; Lung; Lung Diseases, Interstitial; Narcotics; Oxygen Inhalation Therapy; Piperazines; Prednisolone; Purines; Pyridones; Quality of Life; Sildenafil Citrate; Sulfones; Thalidomide; Tubulin Modulators

2013

Trials

5 trial(s) available for pirfenidone and Dyspnea

ArticleYear
Prolonged-release pirfenidone in patients with pulmonary fibrosis as a phenotype of post-acute sequelae of COVID-19 pneumonia. Safety and efficacy.
    Respiratory medicine, 2023, Volume: 217

    Topics: COVID-19; Disease Progression; Dyspnea; Humans; Idiopathic Pulmonary Fibrosis; Phenotype; Pneumonia; Pyridones

2023
Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
    Respiratory medicine, 2019, Volume: 153

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Carbon Monoxide; Case-Control Studies; Dyspnea; Exercise Tolerance; Female; Hospitalization; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Mortality; Placebos; Pulmonary Diffusing Capacity; Pyridones; Respiratory Function Tests; Treatment Outcome; Vital Capacity

2019
Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis.
    The European respiratory journal, 2019, Volume: 54, Issue:3

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Dyspnea; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Quality of Life; Severity of Illness Index; Sex Factors; Surveys and Questionnaires; Time Factors; Treatment Outcome; Vital Capacity

2019
Predictors of Mortality Poorly Predict Common Measures of Disease Progression in Idiopathic Pulmonary Fibrosis.
    American journal of respiratory and critical care medicine, 2016, 09-15, Volume: 194, Issue:6

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Dyspnea; Female; Hospitalization; Humans; Idiopathic Pulmonary Fibrosis; Male; Models, Statistical; Proportional Hazards Models; Pyridones; Risk Assessment; Risk Factors; Surveys and Questionnaires; Vital Capacity

2016
Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function.
    The European respiratory journal, 2016, Volume: 48, Issue:3

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Dyspnea; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Respiratory Function Tests; Surveys and Questionnaires; Tidal Volume; Treatment Outcome; Vital Capacity

2016

Other Studies

7 other study(ies) available for pirfenidone and Dyspnea

ArticleYear
Case 10-2019: A 69-Year-Old Man with Progressive Dyspnea.
    The New England journal of medicine, 2019, Mar-28, Volume: 380, Issue:13

    Topics: Aged; Alveolitis, Extrinsic Allergic; Biopsy; Diagnosis, Differential; Dyspnea; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Male; Pyridones; Radiography, Thoracic; Sarcoidosis; Tomography, X-Ray Computed

2019
Pirfenidone Improves Familial Idiopathic Pulmonary Fibrosis without Affecting Serum Periostin Levels.
    Medicina (Kaunas, Lithuania), 2019, May-17, Volume: 55, Issue:5

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cell Adhesion Molecules; Cough; Disease Progression; Dyspnea; Humans; Idiopathic Pulmonary Fibrosis; Male; Mucin-1; Pulmonary Surfactant-Associated Protein A; Pulmonary Surfactant-Associated Protein D; Pyridones

2019
Challenges in IPF diagnosis, current management and future perspectives: Patient case 1.
    Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2015, Aug-03, Volume: 32 Suppl 1

    Topics: Aged; Dyspnea; Early Diagnosis; Female; Follow-Up Studies; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Respiratory Function Tests; Risk Assessment; Time Factors; Tomography, X-Ray Computed; Treatment Outcome

2015
A Patient with Idiopathic Pleuroparenchymal Fibroelastosis Showing a Sustained Pulmonary Function due to Treatment with Pirfenidone.
    Internal medicine (Tokyo, Japan), 2016, Volume: 55, Issue:5

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Dyspnea; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; Pleural Diseases; Pyridones; Radiography, Thoracic; Respiratory Physiological Phenomena; Time Factors; Treatment Outcome; Vital Capacity; Weight Loss

2016
Marked Improvement with Pirfenidone in a Patient with Idiopathic Pulmonary Fibrosis.
    Internal medicine (Tokyo, Japan), 2016, Volume: 55, Issue:6

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cough; Disease Progression; Dyspnea; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Tomography, X-Ray Computed; Treatment Outcome; Vital Capacity

2016
Assessing the Therapeutic Response to Pirfenidone in Idiopathic Pulmonary Fibrosis: Can We Do Better than with Forced Vital Capacity Alone?
    Lung, 2017, Volume: 195, Issue:1

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Disease-Free Survival; Dyspnea; Female; Forced Expiratory Volume; Humans; Idiopathic Pulmonary Fibrosis; Longitudinal Studies; Male; Middle Aged; Pilot Projects; Prospective Studies; Pulmonary Diffusing Capacity; Pyridones; Treatment Outcome; Vital Capacity; Walk Test

2017
A rare cause of interstitial lung disease: Hermansky-Pudlak syndrome.
    Tuberkuloz ve toraks, 2011, Volume: 59, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Dyspnea; Fatal Outcome; Hermanski-Pudlak Syndrome; Humans; Male; Middle Aged; Pulmonary Fibrosis; Pyridones; Radiography, Thoracic; Respiratory Insufficiency; Tomography, X-Ray Computed

2011